Radiopharm Theranostics (RADX) Common Equity (2024 - 2025)
Radiopharm Theranostics (RADX) reported Common Equity of $274565.9 for Q2 2025, up 52.31% year-over-year from $180264.9 in Q2 2024, and up 52.31% quarter-over-quarter from $180264.9 in Q2 2024.
Radiopharm Theranostics (RADX) Common Equity (2024 - 2025) Analysis & Trends
Radiopharm Theranostics (RADX) has 2 years of Common Equity data on file, last reported at $274565.9 in Q2 2025.
- Common Equity for Q2 2025 came in at $274565.9, up 52.31% year-over-year; the trailing twelve-month figure through Jun 2025 was $274565.9 (up 52.31% YoY), and the FY2025 annual result was $42.9 million, up 56.73% from the prior year.
- Common Equity climbed to $274565.9 in Q2 2025 per RADX's latest filing, from $180264.9 in the prior quarter.
- Over five years, Common Equity peaked at $274565.9 in Q2 2025 and troughed at $180264.9 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Radiopharm Theranostics | 5.82 Bn | 5.81 Bn | - | 274,565.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 274,565.91 |
| Jun 30, 2024 | 180,264.85 |